This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Can CryoPort, Inc. (CYRX) Climb 36% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CryoPort, Inc. (CYRX) points to a 36.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -13.33% and 0.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Daseke (DSKE) Q2 Earnings Lag Estimates
by Zacks Equity Research
Daseke (DSKE) delivered earnings and revenue surprises of -36.84% and 9.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Schneider National (SNDR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Schneider National (SNDR) delivered earnings and revenue surprises of 5.88% and 4.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -55% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
New Strong Sell Stocks for March 10th
by Zacks Equity Research
BSET, CYRX, and DIN have been added to the Zacks Rank #5 (Strong Sell) List on March 10, 2022.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -780% and 2.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why CryoPort, Inc. (CYRX) is Poised for a Turnaround After Losing 22.8% in 4 Weeks
by Zacks Equity Research
CryoPort, Inc. (CYRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Expeditors International (EXPD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Expeditors International (EXPD) delivered earnings and revenue surprises of 31.68% and 26.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CryoPort, Inc. (CYRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Forward Air (FWRD) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Forward Air (FWRD) delivered earnings and revenue surprises of 9.38% and 4.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -20.00% and 3.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CryoPort, Inc. (CYRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -23.08% and 9.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CryoPort, Inc. (CYRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cryoport (CYRX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cryoport (CYRX) has been struggling lately, but the selling pressure may be coming to an end soon.
4 Sector ETFs & Stocks to Play U.S. June Inflation Data
by Sanghamitra Saha
Annual inflation rate in the United States accelerated to 5.4% year over year in June of 2021 from 5% in May.
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of 38.10% and 13.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -86.67% and 11.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?